62 related articles for article (PubMed ID: 37341821)
1. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
Martinez-Soria N; McKenzie L; Draper J; Ptasinska A; Issa H; Potluri S; Blair HJ; Pickin A; Isa A; Chin PS; Tirtakusuma R; Coleman D; Nakjang S; Assi S; Forster V; Reza M; Law E; Berry P; Mueller D; Osborne C; Elder A; Bomken SN; Pal D; Allan JM; Veal GJ; Cockerill PN; Wichmann C; Vormoor J; Lacaud G; Bonifer C; Heidenreich O
Cancer Cell; 2018 Oct; 34(4):626-642.e8. PubMed ID: 30300583
[TBL] [Abstract][Full Text] [Related]
2. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
Trinh BQ; Ummarino S; Zhang Y; Ebralidze AK; Bassal MA; Nguyen TM; Heller G; Coffey R; Tenen DE; van der Kouwe E; Fabiani E; Gurnari C; Wu CS; Angarica VE; Yang H; Chen S; Zhang H; Thurm AR; Marchi F; Levantini E; Staber PB; Zhang P; Voso MT; Pandolfi PP; Kobayashi SS; Chai L; Di Ruscio A; Tenen DG
Blood; 2021 Oct; 138(15):1331-1344. PubMed ID: 33971010
[TBL] [Abstract][Full Text] [Related]
3. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
Loke J; Assi SA; Imperato MR; Ptasinska A; Cauchy P; Grabovska Y; Soria NM; Raghavan M; Delwel HR; Cockerill PN; Heidenreich O; Bonifer C
Cell Rep; 2017 May; 19(8):1654-1668. PubMed ID: 28538183
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of RUNX3 inhibits normal human myeloid development.
Menezes AC; Jones R; Shrestha A; Nicholson R; Leckenby A; Azevedo A; Davies S; Baker S; Gilkes AF; Darley RL; Tonks A
Leukemia; 2022 Jul; 36(7):1769-1780. PubMed ID: 35490198
[TBL] [Abstract][Full Text] [Related]
5. Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells.
Nafria M; Keane P; Ng ES; Stanley EG; Elefanty AG; Bonifer C
Cell Rep; 2020 May; 31(8):107691. PubMed ID: 32460028
[TBL] [Abstract][Full Text] [Related]
6. Developmental-stage-dependent transcriptional response to leukaemic oncogene expression.
Regha K; Assi SA; Tsoulaki O; Gilmour J; Lacaud G; Bonifer C
Nat Commun; 2015 May; 6():7203. PubMed ID: 26018585
[TBL] [Abstract][Full Text] [Related]
7. RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Wang S; Liu Y; Zhao X; Wang X; Lou J; Jin P; Zhang Y; Yu J; Wang K
Br J Haematol; 2024 May; ():. PubMed ID: 38802066
[TBL] [Abstract][Full Text] [Related]
8. RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development.
Carratt SA; Kong GL; Coblentz C; Schonrock Z; Maloney L; Weeder B; Yashar W; Callahan R; Blaylock H; Coleman C; Coleman D; Braun TP; Maxson JE
Leukemia; 2023 May; 37(5):1141-1146. PubMed ID: 36894620
[No Abstract] [Full Text] [Related]
9. RUNX1 regulates promoter activity in the absence of cognate DNA binding motifs.
Woodworth AM; Hardy K; Taberlay PC; Dickinson JL; Holloway AF
J Cell Biochem; 2024 Jun; 125(6):e30570. PubMed ID: 38616697
[TBL] [Abstract][Full Text] [Related]
10. Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency.
Zhang W; Li J; Yamamoto K; Goyama S
Int J Hematol; 2024 May; ():. PubMed ID: 38702444
[TBL] [Abstract][Full Text] [Related]
11. Polyester-Based Dendrimer Nanoparticles Combined with Etoposide Have an Improved Cytotoxic and Pro-Oxidant Effect on Human Neuroblastoma Cells.
Alfei S; Marengo B; Domenicotti C
Antioxidants (Basel); 2020 Jan; 9(1):. PubMed ID: 31935872
[TBL] [Abstract][Full Text] [Related]
12. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
Martinez-Soria N; McKenzie L; Draper J; Ptasinska A; Issa H; Potluri S; Blair HJ; Pickin A; Isa A; Chin PS; Tirtakusuma R; Coleman D; Nakjang S; Assi S; Forster V; Reza M; Law E; Berry P; Mueller D; Osborne C; Elder A; Bomken SN; Pal D; Allan JM; Veal GJ; Cockerill PN; Wichmann C; Vormoor J; Lacaud G; Bonifer C; Heidenreich O
Cancer Cell; 2019 Apr; 35(4):705. PubMed ID: 30991028
[No Abstract] [Full Text] [Related]
13. Corrigendum to 'FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia'.
Br J Haematol; 2024 Mar; 204(3):1120. PubMed ID: 38329292
[No Abstract] [Full Text] [Related]
14. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.
Marion W; Koppe T; Chen CC; Wang D; Frenis K; Fierstein S; Sensharma P; Aumais O; Peters M; Ruiz-Torres S; Chihanga T; Boettcher S; Shimamura A; Bauer DE; Schlaeger T; Wells SI; Ebert BL; Starczynowski D; da Rocha EL; Rowe RG
Leukemia; 2023 Aug; 37(8):1698-1708. PubMed ID: 37391485
[TBL] [Abstract][Full Text] [Related]
15. RUNX1/ETO regulates reactive oxygen species (ROS) levels in t(8,21) acute myeloid leukaemia via FLT3 and RAC1.
Azlan A; Khor KZ; Rajasegaran Y; Rosli AA; Said MSM; Yusoff NM; Moses EJ
Med Oncol; 2023 Jun; 40(7):208. PubMed ID: 37341821
[TBL] [Abstract][Full Text] [Related]
16. A RUNX1/ETO-SKP2-CDKN1B axis regulates expression of telomerase in t (8;21) acute myeloid leukemia.
Moses EJ; Azlan A; Khor KZ; Mot YY; Mohamed S; Seeni A; Barneh F; Heidenreich O; Yusoff N
Cell Mol Life Sci; 2023 Feb; 80(3):70. PubMed ID: 36820913
[TBL] [Abstract][Full Text] [Related]
17. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
18. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
